Decera Clinical Education APP Podcast

In this first of two podcasts, oncologists discuss the latest evidence that informs how they select first-line treatment regimens for patients with metastatic colorectal cancer. Using cases for a patient-centered approach, they explore the recommended testing for mutations and biomarkers that impact metastatic colorectal cancer, how to plan strategies for incorporating novel agents into the treatm...

In this second of two podcasts, two oncologists discuss subsequent therapy for metastatic colorectal cancer, and review cases of patients with metastatic colorectal cancer to discuss testing for mutations and biomarkers, appropriate selection of treatment regimens, and management. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU . Contributors: Joleen Hubbard MD Cathy...

In this podcast, Dr. Alicia Morgans discusses recent data presented at the 2022 ASCO GU Cancers Symposium, including trials evaluating the use of first-line PARP inhibitors in combination with abiraterone for mCRPC, continuation of enzalutamide after progression, and imaging modalities as predictive and prognostic biomarkers. This activity is available for CE/CME credit. Claim your credit at pce.i...

In this second of two podcasts, an expert discuss decision making for subsequent line therapy for advanced gastric cancer, and review cases to illustrate practical considerations, followed by a question-and-answer session. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU . Contributor: David Ilson, MD Dr Ilson:  consulting fees:  Aeris, Amgen, Astellas, AstraZeneca, B...

In this first of two podcasts, an expert discusses the data supporting their selection of first-line treatments for advanced gastric cancer. A case illustrates key takeaways about molecular markers that can impact choice of therapy in gastric cancer, novel and emerging treatments, and prevention and management of treatment-related toxicities. This activity is available for CE/CME credit. Claim you...

In this second episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss how to identify, prevent and mitigate treatment-related adverse events, and review cases with careful considerations for patient-specific factors guiding treatment selection, followed by a question-and-answer session on the management of patients with HCC. This activity is available for CE/CME credit. Claim your...

In this first episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss the latest data supporting their approach to selecting treatment regimens for patients with HCC, with topics including: the current challenges in the management of HCC, recommended initial workup strategies and the evolving treatment landscape in HCC. This activity is available for CE/CME credit. Claim your credit...

In this first of two podcasts, expert faculty review the latest data on the management of advanced urothelial cancer with novel therapies including immune checkpoint inhibitors and antibody-drug conjugates. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU . Contributors: Arjun Balar, MD Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN Dr Balar:  consulting fees:  Bristol-Mye...

In this second of two podcasts, discuss the management of advanced urothelial cancer with novel therapies and how to address adverse events, and concludes the episode with a review of audience questions and patient cases. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU . Contributors: Arjun Balar, MD Rana R. McKay, MD Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN Dr Bala...

In this second of two podcasts, Rana R. McKay, MD, and Arjun Balar, MD, and moderator Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN, discuss the optimal treatment selection and management of adverse events for patients with metastatic and nonmetastatic castration-resistant or castration-sensitive prostate cancers, including the use of taxanes, androgen receptor agonists, and other therapies. This acti...

In this first of two podcasts, Dr. Rana R. McKay discusses the optimal treatment selection and management of adverse events for patients with metastatic and nonmetastatic castration-sensitive prostate cancer (CRPC), including the use of taxanes, androgen receptor agonists, and other therapies. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU . Contributors: Arjun Bala...

In this second of two podcasts, Tracey M. Piparo, PA-C and Martin C. Mahoney, MD, PhD discuss barriers to pneumococcal vaccination, especially in the younger risk-based population, and provide specific strategies providers can implement to help improve pneumococcal vaccination coverage rates in effort to decrease the burden of pneumococcal disease. This activity is available for CE/CME credit. Cla...

In this first of two podcasts, Tracey M. Piparo, PA-C and Martin C. Mahoney, MD, PhD discuss the benefits of pneumococcal vaccination, review the types of pneumococcal vaccines currently available, and provide ACIP’s recently updated age-based and risk-based recommendations on when to use the new conjugated pneumococcal vaccines.  This activity is available for CE/CME credit. Claim your credit at...

In this second of 2 podcasts, Tracey Piparo, PA-C and Martin C. Mahoney, MD, PhD provide strategies to overcome HPV vaccination barriers to improve our HPV vaccination rates among eligible individuals.  The podcast includes a discussion of both provider and patient/caregiver barriers as well as specific strategies you can implement, including use of shared-decision making, to help prevent HPV-asso...

Tune into this informative conversation between Tracey M. Piparo, PA-C and Martin C. Mahoney, MD, PhD regarding the appropriate use of HPV vaccines for prevention of HPV-related cancers.  Topics covered in this podcast include an overview of the burden of HPV, HPV vaccination coverage rates across different age groups, eligibility for HPV vaccination, and age-based dosing schedules. This activity...

In this second of two podcasts, hear Dr Robin Dore discuss key information from ACR Convergence 2021 , including the use of COVID-19 vaccine in immunosuppressed adults with autoimmune diseases; the cardiovascular risk of hydroxychloroquine in rheumatoid arthritis; whether the boxed warning for romosozumab helps prevent inappropriate use in postmenopausal women with osteoporosis and a history of my...

In this first of two podcasts, hear Dr Vibeke Strand discuss key information from ACR Convergence 2021 , including the potential to intervene in patients who are at high risk for developing rheumatoid arthritis; whether vitamin D3 and n-3 fatty acids can prevent autoimmune disease; the Food and Drug Administration’s perspective on the safety of Janus kinase inhibitors; and results from a phase 3b/...

In this second of 2 podcasts, Tish Haight, ACNP, CCRN, BC, and January-Jill Ogoy, DHSc, MPA, PA-C, provide clinical perspective on selected practice changing abstracts, covering a variety of topics from the CHEST 2021 Annual Meeting. Topics covered in this podcast include a chronic cough treatment in the pipeline, inhaled corticosteroid use and COVID-19 outcomes, and paradoxical bronchospasm with...

In this first of 2 podcasts, Tish Haight, ACNP, CCRN, BC, and January-Jill Ogoy, DHSc, MPA, PA-C, provide clinical perspective on selected practice changing abstracts, covering a variety of topics from the CHEST 2021 Annual Meeting. Topics covered in this podcast include a comparison of idiopathic pulmonary arterial hypertension outcomes, an evaluation of combination therapies for the treatment of...

In this podcast, an expert offers his perspective on the role of newer agents in atopic dermatitis—when they’re indicated, how to use them, where they fit on the therapeutic ladder, and adverse effects to monitor for. Also, tips on how to individualize therapy and anticipate adherence issues. The podcast concludes with thoughts on how to address some frequently-asked questions from patients and ca...

Targeted therapies address the underlying pathways that cause airflow obstruction in patients with asthma, including a number of biologic therapies that have been approved. Omalizumab targets IgE (approved for moderate to severe persistent asthma). Three agents target IL-5, which plays a key role in the activation of eosinophils, and are approved for severe eosinophilic asthma: mepolizumab, resliz...

Asthma is now recognized as a heterogeneous, multidimensional disease that involves numerous pathophysiologic factors, including bronchiolar inflammation with airway constriction and resistance. The identification of distinct patient populations (phenotypes/endotypes) is increasingly being recognized as an important strategy for optimizing the management of patients with asthma. Asthma phenotype i...

An early, accurate diagnosis and appropriate pharmacologic and nonpharmacologic treatment of IPF are imperative for improved outcomes. Given the poor prognosis of IPF, educating and involving patients in their care is necessary for optimal quality of life. In this podcast,  Corinne R. Young, MSN, FNP-C, FCCP, provides an overview of key points addressed by expert faculty during a live webinar.  Pl...

Effective influenza management during the COVID-19 pandemic requires a knowledge of emerging diagnostics, immunizations, and antiviral agents. The armamentarium for influenza treatment now includes multiple classes including neuraminidase inhibitors (eg, oseltamivir) and the polymerase acidic endonuclease inhibitor, baloxavir. In this podcast, Mary Knudtson, DNSc, NP, FAAN, asks questions from hea...

Influenza management continues to increase in complexity as new diagnostic, prevention, and treatment options emerge and the COVID-19 pandemic adds additional considerations. Antiviral therapies for influenza now include neuraminidase inhibitors (eg, oseltamivir) and baloxavir. In this podcast, Lawrence Herman, DMSc, MPA, PA-C, asks timely influenza questions from healthcare professionals to infec...